$BIO News Article - New Data Shows AbbVie's VENCLYXTO /VENCLEXTA Fixed Duration Combination Demonstrates Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients after Three Years off Treatment
https://marketwirenews.com/news-releases/new-...73036.html